It is really good to have the video here. Yesterday's conf. call was also very informative, particularly the Q&A session on VX-222. I hope this along with TVR, 770, 809, and 509 are those four or five products that Emmens promised to be visible a year from now. I have been listening to the Q&A over and over again. Emmens made some bold statements in the interview with Mike Huckman, but if you have followed the history of Gilead's drugs, you cannot find a sigle product that was organically generated as TVR is.
Very few "small" biotech companies have an executive team with the experience in the pharmaceutical industry and successful records that Messers Emmens and Graves bring to Vertex. With 1,400 employess worldwide, ready to take multiple drugs in its pipline through the approval process and to market in the nest two years, Vertex has an infrastructure in place that it is on the verge of making Mr. Emmens goal a reality. The current market cap of Vertex affirms the street's opinion that the company has the potential to be the next big independent bio-pahrma company success story. The next 12 to 24 months of cinical data will certainly be the "rocket fuel" that propels this company into the likes of the large biotechs Mr. Emmens referred to, and shorts had better be wary that he has the track record and the company's pipeline of drug candidates has the market potential to pull it off.
Agree 99%. I would agree 100% with you if you had said we'll see launch of Telaprevir in the next 12 months. Please read the WSJ article the following link opens. The FDA allowed the distribution of Shire's drug Vela before its formal approval of the drug. Shire just finished its Phase III for Vela, and it is the company where Emmens is also the Chairman. As you implied, under the leadership of Emmens, who had been the CEO of Shire for 5 years until last year, Shire has developed Vela and Replagal and has launched Replagal and will launch Vela to treat Gaucher and Fabry diseases. This is an interesting development because Genzyme, another Mass. company, have been marketing Cerezyme and Fabrazyme for the diseases. Only a temporary shortage of the drugs led to the FDA action to permit Vela and Replagal to be marketed in the US. Emmens may do it again at Vertex to beat the schedule and launch Telaprevir at mid-2010. This increases the credibility of Merriman which was predicting a 2010 launch.